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Abstract
 
The activator protein 1 (AP-1) transcription factor is a key participant in the control of T cell
proliferation, cytokine production, and effector function. In the immune system, AP-1 activity
 
is highest in T cells, suggesting that a subset of T cell–specific coactivator proteins exist to
selectively potentiate AP-1 function. Here, we describe that the expression of 
 
Schnurri-3
 
, also
known as 
 
 
 
 recognition component (KRC), is induced upon T cell receptor signaling in T
cells and functions to regulate the expression of the interleukin 2 (IL-2) gene. Overexpression
of KRC in transformed and primary T cells leads to increased IL-2 production, whereas dominant-
negative KRC, or loss of KRC protein in KRC-null mice, results in diminished IL-2 production.
KRC physically associates with the c-Jun transcription factor and serves as a coactivator to augment
AP-1–dependent IL-2 gene transcription.
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Introduction
 
The zinc finger transcription factor 
 
 
 
 recognition component
(KRC), a large protein composed of 2,282 amino acids,
was originally isolated by virtue of its ability to bind to the
recombination signal sequence (Rss) flanking the V, D, and
J gene segments of the immunoglobulin gene (1–7). Sequence
analysis revealed that KRC contains a zinc finger acidic
domain structure (ZAS) composed of a pair of Cys2-His2
zinc fingers followed by a Glu- and Asp-rich acidic domain
and five copies of the ser/Thr-Pro-X-Arg/Lys sequence
thought to bind DNA. ZAS domain proteins are a family
of enhancer binding proteins for the 
 
 
 
B motif, and KRC
recombinant proteins can bind in vitro to the 
 
 
 
B motif as
well as to the Rss sequence (2, 8) in highly ordered complexes
(1, 9). KRC has been shown to regulate transcription of
the mouse metastasis–associated gene S100A4/mts1 (10,
11), and down-regulation of KRC expression affects prolif-
eration and cell death (12, 13). However, our recent studies
have suggested that KRC can also act as an adaptor protein.
Recently, we described a novel function for KRC in
regulating patterns of gene activation in response to proin-
flammatory stimuli (14). We demonstrated that KRC interacts
with the adaptor protein TRAF2 to inhibit both nuclear
factor (NF) 
 
 
 
B and c-Jun NH
 
2
 
-terminal kinase (JNK)/
SAPK-mediated responses, including apoptosis and TNF
 
 
 
cytokine gene expression. Thus, overexpression of sense
KRC inhibited, whereas antisense KRC or a dominant-
negative KRC enhanced, NF
 
 
 
B-dependent transactivation
and JNK phosphorylation. Although KRC has been shown
to bind DNA, in our studies, its effect on gene activation
could clearly be ascribed to indirect mechanisms.
KRC was isolated from a thymocyte cDNA library, and
given the critical role of the NF
 
 
 
B and JNK pathways in
regulating CD4 T cell activation, effector function, and
cytokine gene expression as well as T cell survival and death
(15–17); we searched for a function of KRC in T cells.
Activator protein 1 (AP-1) function is critical for optimal T
cell development, activation, and differentiation, as revealed
by genetic evidence (18). Furthermore, loss of AP-1 tran-
scriptional activity leads to T cell anergy, further highlighting
the importance of this transcription factor in the immune
system (19, 20). Here, we demonstrate that KRC enhances
endogenous IL-2 production in both transformed and primary
T cells. More importantly, CD4 T cells from KRC-deficient
mice that we have generated produce significantly less IL-2
upon TCR stimulation compared with wild-type CD4 T
cells. We show that KRC physically interacts with the tran-
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scription factor c-Jun and enhances AP-1 function in the
context of the IL-2 promoter.
 
Materials and Methods
 
Reagents and Antibodies.
 
PMA, ionomycin, rottlerin, and the
MEK1 inhibitor were purchased from Calbiochem. Staphylococ-
cus enterotoxin E (SEE) was purchased from Toxin Technology;
anti-Myc, anti–c-Jun, anti-His, and anti-Gal4 antibodies were
obtained from Santa Cruz Biotechnology, Inc.; and anti-Flag an-
tibody was obtained from Sigma-Aldrich.
 
Transfection and Luciferase Assays.
 
For each transfection, 5 
 
 
 
10
 
6
 
 Jurkat cells were incubated with either IL-2–Luc, NFAT/
AP1-Luc, or AP1-Luc reporter DNA together with pEF vector
or pEF-KRC and CMV-
 
 
 
GAL as normalization control in 0.4
ml of RPMI 1640 and transfected by electroporation (260 V, 975
 
 
 
F). R. Flavell and R. Davis provided the AP-1 luciferase and
N17R as dominant-negative and MKK7 constructs, respectively.
Transfected cells were cultured at 37
 
 
 
C for 20 h in RPMI 1640
medium (GIBCO BRL) supplemented with 10% FBS. Trans-
fected cells were stimulated with 50 ng/ml PMA and 2 
 
 
 
M ion-
omycin for 6 h before luciferase (Promega) and 
 
 
 
-galactosidase
assays (Galacton-PLUS substrate system; TROPIX, Inc.).
 
Western Blot Analysis and Reverse Transcription–PCR.
 
Total
RNA was isolated from T cells using TRIzol reagent (GIBCO
BRL). 1 
 
 
 
g of total RNA was reverse transcribed using iScript
cDNA Synthesis Kit (Bio-Rad Laboratories). PCR was per-
formed with 2 
 
 
 
M of each primer and 2.5 U of platinum high
fidelity enzyme (Invitrogen) according to the manufacturer’s
instructions using the following primers: IL-2F, 5
 
 
 
-CAAGA-
ATCCAAACTCACCAG-3
 
 
 
; IL-2R, 5
 
 
 
-TAGCAACCATAC-
ATTCAACAA-3
 
 
 
; KRCF, 5
 
 
 
-CTCCAATACAGAATTCAA-
GGGC-3
 
 
 
; and KRCR, 5
 
 
 
-TTTAGGTTGGCCAGTGTGT-
GTG-3
 
 
 
.
For Western blot analyses, 293 cells were transfected with Ef-
fectene (QIAGEN) according to the manufacturer’s instructions.
To prepare cell extracts, cells were washed twice with PBS and
lysed for 20 min on ice in 1 ml Triton X-100 lysis buffer (25 mM
Tris, pH 7.5, 250 mM NaCl, 1% Triton X-100, 10% glycerol, 5
mM EDTA, 1 mM EGTA, 0.5 mM DTT, and complete pro-
tease inhibitor mixture; Roche Molecular Biochemicals). Lysates
were cleared by centrifugation for 10 min at 14,000 revolutions/
min, precleared with 30 
 
 
 
l of protein A/G–Sepharose beads, and
incubated overnight with the indicated antibody. Subsequently,
30 
 
 
 
l of protein A/G–Sepharose beads was added, and lysates
were incubated at 4
 
 
 
C for an additional 2 h. The immunoprecip-
itates were washed five times with the lysis buffer, resuspended in
SDS sample buffer, and heated at 95
 
 
 
C for 5 min. Immunopre-
cipitated proteins were separated by SDS-PAGE and transferred
to PVDF membranes (Bio-Rad Laboratories). Western blotting
was performed by probing with primary antibody followed by
horseradish peroxidase–conjugated and goat anti–rabbit IgG
(Zymed Laboratories) and enhanced chemiluminescence accord-
ing to the manufacturer’s instructions (Amersham Biosciences).
 
Raji and SEE Stimulation.
 
Jurkat cells were transfected by
electroporation and incubated for 20 h at 37
 
 
 
C before stimulation
for 8 h with the Raji B cell line and SEE using Raji cells (1:1
with Jurkat cells) and 200 ng/ml SEE.
 
In Vitro Kinase Assays.
 
Jurkat cells were transfected with
Flag-JNK2 together with pEF or pEF-KRC (KRC cDNA driven
by the elongation factor promoter), and 24–48 h after transfec-
tion, anti-Flag antibody was used to immunoprecipitate JNK2.
 
The kinase reaction was performed at 30
 
 
 
C for 30 min with 1 
 
 
 
g
GST–c-Jun, 10 
 
 
 
Ci 
 
 
 
-[
 
32
 
P]ATP, and 10 
 
 
 
m ATP in 30 
 
 
 
l of ki-
nase buffer (20 mM Hepes, pH 7.4, 10 mM MgCl
 
2
 
, 25 mM
 
 
 
-glycerophosphate, 50 
 
 
 
m Na
 
3
 
VO
 
4
 
, and 1 mM DTT).
 
Pull Down Assays.
 
In vitro–translated c-Jun ([
 
35
 
S]methionine
labeled) and His-KRCtr were incubated for 2 h at 4
 
 
 
C in binding
buffer (PBS, 0.25% NP-40, 1 mM PMSF, and 0.25 mM DTT),
incubated for 2 h with the anti-HIS antibody (Santa Cruz Bio-
technology, Inc.), 30 
 
 
 
l of protein A/G–Sepharose beads was
added, and the reaction was incubated at 4
 
 
 
C for an additional
2 h. The immunoprecipitates were washed five times with the
binding buffer, resuspended in SDS sample buffer, and heated at
95
 
 
 
C for 5 min.
 
Retroviral Gene Transduction.
 
Activated CD4 T cells were
transduced by RV, RV-KRC, or RV-ZAS2 as described previ-
ously (21).
 
Generation of KRC-deficient Mice and T Cell Stimulation.
 
ES
cells were generated in which the entire 5.4-kb exon 2 of KRC
was replaced by a neomycin cassette, resulting in an allele that pro-
duces no KRC protein. KRC
 
 
 
/
 
 
 
 ES cells transmitted the dis-
rupted allele to 129/B6 offspring. Heterozygous pups were back-
crossed to wild-type B6 mice. Mice analyzed were progeny of
intercrosses between heterozygous F3 generation backcrossed
129/B6 mice. CD4 T cells were purified by positive selection
from spleen and lymph nodes of 6–8-wk-old male KRC
 
 
 
/
 
 
 
 and
KRC
 
 
 
/
 
 
 
 littermates using magnetic beads according to the manu-
facturer’s instructions (Miltenyi Biotec). Cells were stimulated at
10
 
6
 
 cells/ml with 1.0 
 
 
 
g/ml plate-bound anti-CD3 plus 0.5 
 
 
 
g/
ml anti-CD28. 24 h later, supernatants were collected and ana-
lyzed for IL-2 levels by ELISA. Additionally, cells were stimulated
for 72 h in the presence of 200 U/ml of human IL-2, and super-
natants were collected and analyzed for IFN
 
 
 
 levels by ELISA.
 
Results
 
KRC Expression Is Induced upon Signals That Trigger Acti-
vation of CD4 T Cells.
 
It was shown previously that KRC
is expressed in cells of the immune system including T
cells, B cells, and macrophages (unpublished data). To de-
termine whether the level of KRC transcripts changes
Figure 1. KRC expression increases in CD4 cells upon activation. Primary
C57/B6 CD4  T cells were stimulated with anti-CD3 (2.0  g/ml)/anti-
CD28 (1.0  g/ml) antibodies for the indicated times. RNA was prepared
and KRC expression was determined by RT-PCR, with  -actin as an
internal control. 
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upon activation in CD4 T cells, RT-PCR analysis was
performed (Fig. 1). KRC expression was induced with
very rapid kinetics (within 20 min) in CD4
 
 
 
 T cells upon
activation by CD3/CD28 stimulation, and increased levels
of KRC transcripts were seen throughout the duration of
primary CD3/CD28 stimulation, up to 48 h. Given its
rapid pattern of induction after T cell activation and its sus-
tained increase in expression, we searched for a potential
role for KRC in events occurring downstream of early T
cell activation, such as entry into the cell cycle and induc-
tion of the cytokine IL-2 (22).
 
KRC Overexpression Increases, whereas KRC Loss Decreases
Endogenous IL-2 Production in Both Transformed and Primary
T Cells.
 
IL-2 promoter activation requires antigen recep-
tor engagement plus an accessory signal usually supplied by
an antigen-presenting cell (22). Agents that bypass these re-
ceptors, such as PMA and ionomycin, can mimic T cell ac-
tivation in the human T cell lymphoma Jurkat. To assess
the function of KRC in T cells, Jurkat cells, which express
barely detectable levels of endogenous KRC protein by
Western blot analysis, were stably transfected with a plas-
mid encoding full-length KRC (pEF-KRC) or with vec-
tor-only control (pEF). G418 drug-resistant Jurkat clones
were expanded and analyzed for IL-2 secretion after activa-
tion. Clones stably expressing KRC showed clear increases
in KRC protein levels, as detected by Western blotting
(unpublished data). We observed that all clones expressing
pEF-KRC produced substantially greater amounts of IL-2
upon PMA and ionomycin treatment than activated Jurkat
clones transfected with the control vector (Fig. 2 A). KRC
overexpression alone was not sufficient to induce IL-2 se-
cretion because no IL-2 was detected in the culture super-
natants of unstimulated KRC-overexpressing clones (un-
published data). These results suggested that KRC is able to
boost IL-2 secretion in concert with signals emanating
from the TCR.
Although the Jurkat model has proved valuable to dissect
pathways of T cell signaling, certain observations made in
Jurkat cells are irreproducible in primary T cells (23, 61).
Therefore, we studied the effects of KRC overexpression
in primary CD4 T cells using a retroviral delivery system.
We generated bicistronic retroviral vectors encoding full-
length KRC, the KRC ZAS2 domain (which we have
previously shown acts as a dominant negative in the con-
text of KRC-mediated inhibition of TNF-induced NF
 
 
 
B
activation; reference 14), and control GFP. Purified CD4 T
cells were infected with these retroviruses 36 h after pri-
mary activation with both anti-CD3 and anti-CD28 and
sorted by flow cytometry for GFP expression 24 h after in-
fection. The ability of each population to produce IL-2 af-
ter subsequent activation by anti-CD3 or anti-CD3 plus
CD28 was measured at 24 h after stimulation. As shown in
Fig. 2 B, CD4 cells transduced with full-length KRC pro-
duced higher amounts (approximately three- to fourfold
Figure 2. KRC overexpression
increases, whereas KRC loss
decreases endogenous IL-2 pro-
duction. (A) Jurkat T cells were
stably transfected with vector
(pEF) or KRC expression plas-
mids. Stable clones were stimu-
lated for 18 h with 50 ng/ml
PMA plus 2  M ionomycin, and
IL-2 production was measured
by ELISA. (B) Primary CD4  T
cells were activated for 36 h and
subsequently transduced with
control (RV), KRC, or KRC
dominant-negative (ZAS2) bicis-
tronic GFP-expressing retrovi-
ruses.  GFP-positive cells were
sorted and stimulated for 24 h
with anti-CD3 or anti-CD3/
anti-CD28 antibodies and IL-2
production was measured by
ELISA. (C) CD4 T cells from
KRC /  or  /  mice were stimu-
lated with anti-CD3 (1.0  g/ml)/
CD28 (0.5  g/ml) antibodies for
24 h, and IL-2 production was
measured by ELISA. (D) CD4 T
cells from KRC /  or  /  mice
were stimulated with anti-CD3/
CD28 antibodies for 72 h in the
presence of 200 U/ml of human
IL-2. IFN  production was
measured by ELISA. Data shown
are representative of four inde-
pendent experiments with similar
results. 
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increase) of IL-2 than CD4 cells infected with the GFP
control retrovirus. Furthermore, CD4 cells transduced with
the dominant negative KRC ZAS2 domain construct pro-
duced significantly less IL-2 than both the full-length KRC
and GFP control transduced cells. These data are consistent
with the notion that the ZAS2 domain interferes with en-
dogenous KRC activity in T cells to prevent optimal ex-
pression of IL-2.
To further analyze the role of KRC in regulating endog-
enous IL-2 expression, we analyzed CD4 cells purified
from KRC-deficient mice. A detailed description of the
generation and phenotypic characterization of these mice
will be presented elsewhere (unpublished data). In brief,
lymphoid development in these mice appears normal, with
normal numbers of CD4
 
 
 
 T cells isolated from spleen and
lymph nodes. Additionally, resting CD4 cells recovered ap-
peared phenotypically normal based on expression of matu-
ration markers such as CD4, CD62L, CD25, CD69, and
TCR
 
 
 
 (unpublished data). As shown in Fig. 2 C, KRC
 
 
 
/
 
 
 
CD4 cells activated in vitro for 24 h by CD3/CD28 stimu-
lation produced 10-fold less IL-2 than CD4 cells from
wild-type littermates. However, IFN
 
 
 
 production by these
cells after 72 h of primary stimulation in the presence of ex-
cess exogenous IL-2 was normal (Fig. 2 D), suggesting that
the deficiency of KRC in these cells does not globally in-
hibit activation-induced cytokine production. We con-
clude that KRC is a positive regulator of IL-2 production
both in Jurkat cells and, more importantly, in primary CD4
T cells.
 
KRC Overexpression Increases the Transcription of the IL-2
Gene.
 
The production of IL-2 by T cells is regulated at
multiple levels, including transcription, mRNA stability,
and rate of protein secretion (24, 25). To define at which
stages KRC acts, we first measured levels of IL-2 mRNA
transcripts by semi-quantitative RT-PCR in Jurkat T cells
stably transfected with full-length KRC. As seen in Fig. 3
A, Jurkat clones overexpressing KRC displayed higher lev-
els of IL-2 transcripts when activated than Jurkat clones
Figure 3. KRC overexpression increases
the transcription of the IL-2 gene. (A) Stably
transfected Jurkat T cell clones with vector
(vec) or KRC (JURKAT-KRC) were stim-
ulated with 50 ng/ml PMA plus 2  M ion-
omycin for 6 h. IL-2 mRNA abundance
was determined by RT-PCR with tubulin
as an internal control. (B) Jurkat cells were
transiently transfected with an IL-2–luciferase
reporter (IL-2-LUC) along with Vector,
KRC, or KRCtr (amino acids 204–1,055)
and, in all cases, a CMV– -Gal reporter as
an internal control (Materials and Methods).
24 h later, cells were stimulated with PMA
plus ionomycin for 6 h (top) or Raji cells
loaded with SEE for 8 h (bottom). Luciferase
activity was determined and normalized for
 -galactosidase activity. (C) Jurkat cells
were transiently transfected with NFAT/
AP-1–, NFAT-, or AP-1–Luciferase reporters
and treated as aforemtioned. 
Oukka et al.
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transfected with vector control. Next, we tested whether
KRC was able to directly transactivate a 1.5-kb IL-2 pro-
moter-luciferase reporter in Jurkat cells. Provision of KRC
resulted in an 
 
 
 
10-fold induction of luciferase activity in
Jurkat cells treated with PMA plus ionomycin (Fig. 3 B,
top). Just as KRC overexpression alone did not lead to
spontaneous production of endogenous IL-2, no transacti-
vation by KRC was observed in the absence of PMA/ion-
omycin in these luciferase reporter assays. To provide a
more physiologic signal to activate Jurkat cells, we used a
model system in which Raji B lymphoma cells act as anti-
gen-presenting cells to present SEE to Jurkat. As shown in
Fig. 3 B (bottom), provision of KRC substantially in-
creased (
 
 
 
10-fold) IL-2 promoter activity in this system.
Interestingly, KRC had no effect on IL-2 promoter activity
in the absence of Jurkat activation either by PMA/ionomy-
cin or by antigen/APC. These data further suggest that
KRC expression alone is not sufficient to induce IL-2
mRNA expression; instead, KRC’s ability to enhance IL-2
production relies on endogenous factors found only in acti-
vated T cells.
 
KRC Augments IL-2 Promoter Activity via AP-1.
 
KRC
was originally cloned as a transcription factor, but in our
previous analyses, its effect on gene activation could clearly
be ascribed to its function as an adaptor protein. Neverthe-
less, KRC has been shown to bind both NF
 
 
 
B and Rss tar-
get sites in vitro, and an NF
 
 
 
B site is present in the IL-2
promoter that has been shown to bind the NF
 
 
 
B family
member c-Rel (26). To test whether KRC overexpression
leads to enhanced function of a specific site in the IL-2 pro-
moter and to identify the site, we cotransfected Jurkat cells
with KRC and various deletion constructs of the IL-2 pro-
moter. In initial studies, KRC transactivated a luciferase re-
porter driven by only 200 bp of the IL-2 proximal pro-
moter. The most prominent regulatory sequences in this
region are cis elements that bind members of the NFAT,
NF
 
 
 
B, and AP-1 transcription factor families (25, 27–29),
although the NFAT and NF
 
 
 
B cis elements have been
shown to overlap. Therefore, we tested whether KRC
could transactivate a multimerized linked NFAT/AP-1 tar-
get site, or individual multimerized NFAT or AP-1 target
sites. KRC enhanced PMA/ionomycin-induced transactiva-
tion of a multimerized linked NFAT/AP-1 element and the
isolated, multimerized AP-1 element, but not the NFAT el-
ement (Fig. 3 C). In contrast to AP-1, the PMA/ionomy-
cin-induced activity of NFAT was not further increased by
coexpression of KRC. Therefore, KRC acts at the transcrip-
tional level to increase expression of IL-2 through an AP-1
site–dependent mechanism. Preliminary results show that
KRC overexpression enhances, and that KRC deficiency
decreases, stimulation-induced up-regulation of CD69 (un-
published data), another AP-1 target gene in T cells (45).
 
KRC Does Not Increase AP-1 Expression, Bind the AP-1
Site, nor Alter TCR-mediated Mitogen-activated Protein Kinase
(MAPK) Activity.
 
It was unlikely that KRC, a zinc finger
protein, transactivated the IL-2 promoter through direct
binding to the AP-1 element, especially given our observa-
 
tion that KRC was able to enhance AP-1 activity only
when Jurkat cells were simultaneously stimulated through
the TCR pathway by PMA or antigen/APC. Indeed, in
electrophoretic mobility shift assays, using extracts prepared
from unstimulated Jurkat cells overexpressing KRC, no
binding to a radiolabeled AP-1 site oligonucleotide was de-
tected (unpublished data). Thus, KRC and AP-1 do not
bind the same site within the IL-2 promoter to synergisti-
cally increase promoter activity. Additionally, we observed
that KRC does not increase AP-1 activity by increasing the
expression of c-Jun/c-Fos mRNA (unpublished data).
An alternative explanation was that KRC acts upstream
to enhance posttranslational modifications of AP-1 that in-
crease its activity. For example, NH
 
2
 
-terminal phosphory-
lation of c-Jun or COOH-terminal phosphorylation of
c-Fos have been shown to enhance AP-1 activation down-
stream of the Ras pathway (23, 30, 31). Overexpression of
a dominant-negative Ras blocks TCR-induced AP-1 ac-
tivity (32). More recently, it has been shown that mice de-
ficient in PKC 
 
 
 
 show defective TCR-induced AP-1 acti-
vation, suggesting a role for this kinase in Ras/MAPK/AP-1
activation (33, 34). We determined that both rottlerin, a
PKC   inhibitor, and overexpression of dominant-negative
Ras (RasN17) abolished the ability of KRC to enhance
AP-1 transactivation after PMA/ionomycin stimulation
(Fig. 4 A). These data are consistent with the placement of
KRC downstream of the Ras pathway or with a require-
ment for two distinct, but interconnected, signals for IL-2
promoter transactivation. We favor the latter explanation
because KRC can increase AP-1 activation by Ras but can-
not activate AP-1 on its own. Thus, KRC activation of
AP-1 requires Ras, and KRC can substantially augment
AP-1 activation by the Ras pathway.
KRC may enhance AP-1 function indirectly through
the modulation of MAPK activity, kinases downstream of
Ras that are known to potently stimulate AP-1 function
(30, 31, 50). In T cells, stimulation via the TCR or with
PMA/ionomycin induces the activation of three MAPKs:
extracellular regulated kinase (ERK), p38, and JNK. The
activation of these MAPKS is required for AP-1 transcrip-
tional activity. In particular, JNK has been shown to in-
crease AP-1 transcriptional activity by phosphorylating
c-Jun (35). In initial studies, we determined that KRC
overexpression did not alter levels of transcripts encoding a
series of MAP3, MAP2, and MAP kinases as assessed by
RNase protection assays (unpublished data). To test
whether KRC had any effect on MAPK activity, we used a
sensitive assay (the PathDetect reporting system) to evalu-
ate the effect of KRC on ERK-mediated ELK-1 transacti-
vation and p38-mediated ATF2 transactivation. Jurkat cells
were cotransfected with a pGAL4-UAS-LUC reporter and
expression plasmids encoding GAL4-Elk1 and GAL4-
ATF2 fusion proteins, respectively. KRC was unable to
modulate either MAPK or p38 activity in this assay (Fig. 4
B). We coexpressed KRC with HA-ERK1, myc-ERK2,
Flag-P38, and Flag-JNK2, and measured the activity of
each kinase using an immunoprecipitation kinase assay withKRC Interacts with c-Jun to Regulate IL-2 in T Cells 20
specific substrates: GST-Elk1, GST-ATF2, and GST-Jun
for each MAPK. KRC had no detectable effect on any of
the MAPKs in this assay (Fig. 4 C, results for JNK). We
conclude that KRC does not increase AP-1 activity
through increasing TCR-mediated MAPK activity, al-
though we have observed earlier that KRC down-regulates
TRAF2-mediated JNK activation after TNF  stimulation
in macrophage cell lines (14). Because PMA/ionomycin is
a very poor inducer of JNK activation in T cells, we cannot
rule out that KRC might also down-regulate JNK in T
cells under different circumstances (e.g., CD28 stimula-
tion). However, the ability of KRC to inhibit low levels of
JNK activity after prolonged CD3/CD28 stimulation of
naive Thp cells is unlikely to account for its ability to dra-
matically enhance AP-1 function and IL-2 production.
KRC Physically Interacts with c-Jun and Acts as a Transcrip-
tional Coactivator. We have demonstrated recently that
KRC interacts with the adaptor protein TRAF2 to inhibit
both NF B and JNK/SAPK-mediated responses, including
apoptosis and TNF  cytokine gene expression (14). We
asked whether KRC might, therefore, physically associate
with c-Jun. Expression vectors encoded c-Jun and a trun-
cated myc-tagged version of KRC encoding amino acids
204–1,055 (KRC tr), which includes the third zinc finger
domain, one of the three acidic domains and the putative
NLS sequence that were overexpressed in the 293T kidney
epithelial cell line. Coimmunoprecipitation using a mono-
clonal anti-myc antibody revealed that KRC physically as-
sociated with c-Jun (Fig. 5 A). Furthermore, it demon-
strated that the region of KRC shown to associate with
TRAF2 (amino acids 204–1,055) also interacted with
c-Jun. Similar results were obtained in coimmunoprecipi-
tation of overexpressed full-length KRC with c-Jun, al-
though the absolute amounts of c-Jun obtained were less,
presumably because the full-length KRC protein is poorly
expressed due to its large size (Fig. 5 B). Further mapping
of c-Jun to delineate its interaction site with KRC revealed
that KRC interacts with c-Jun amino acids 1–224 fused to
the DNA binding domain of GAL4, which includes the
transactivation domain (unpublished data). Furthermore,
this association is direct and does not require posttransla-
tional modifications as shown by the interaction of in vitro
translated KRC and c-Jun proteins (Fig. 5 B, right). Fi-
nally, it was important to demonstrate that this association
occurred under physiologic conditions. Untransfected Jur-
kat or EL4 T cell lines were stimulated with PMA/iono-
mycin for 45 min, and AP-1 complexes were purified by
immunoprecipitating c-Jun. Fig. 5 C shows that endoge-
nous KRC is readily detected in these complexes obtained
from stimulated cells.
To further investigate the mechanism via which KRC
serves as an AP-1 coactivator, we activated AP-1 by over-
expressing c-Jun or c-Jun and c-Fos in 293T cells with an
AP-1 luciferase reporter. In this system, overexpression of
KRC enhances both c-Jun and c-Jun plus c-Fos AP-1 ac-
tivity (Fig. 5 d, approximately fivefold). However, the
presence of endogenous AP-1 proteins might complicate
interpretation of these results. Therefore, we fused the Gal4
DNA binding domain to the c-Jun or c-Fos transactivation
domains and cotransfected these chimeric cDNAs with
KRC and a Gal4 binding site–luciferase reporter construct
into 293T cells. The chimeric GAL4-c-Jun, but not
GAL4-c-Fos, protein potently transactivated the reporter
construct in the presence of KRC, demonstrating that
KRC indeed acts as a transcriptional coactivator (Fig. 5 D).
Figure 4. KRC does not modulate MAPK activity. (A) Jurkat cells
were transiently transfected with AP-1–luciferase reporter along with
KRC and RasN17 DN vectors. 24 h later, cells were pretreated with
10  M rottlerin and stimulated for 6 h with PMA plus ionomycin. Luciferase
activity was measured as described in Materials and Methods. (B) Jurkat
cells were transfected with a GAL4 luciferase reporter along with a GAL4
DNA binding domain, GAL4-ATF2, or GAL4-ELK1 with or without
KRC. 24 h later, cells were stimulated with PMA plus ionomycin and
analyzed for luciferase activity as described in Materials and Methods.
(C) Jurkat cells were transiently transfected with FLAG-JNK2, and either
Vector, KRC, or MKK7. 48 h later, cells were stimulated with PMA plus
ionomycin for 6 h, and JNK activity was determined by immunoprecipi-
tation/kinase assay. Equal amounts of FLAG-Jnk2 protein were immuno-
precipitated, as judged by anti-FLAG Western blot (bottom).Oukka et al. 21
In summary, KRC specifically associates with c-Jun under
physiologic conditions and this association augments AP-1
transcriptional activity.
Discussion
Here, we have demonstrated a role for the KRC pro-
tein, a Drosophila schnurri family member, in regulating ex-
pression of the IL-2 gene in T cells. D. schnurri (Shn) pro-
tein functions as a cofactor of the D. schnurri Smad
homologue, dpp, to effect Decapentaplegic signaling dur-
ing embryogenesis (36–41). Schnurri interacts with Mad in a
Dpp-dependent manner, is required for dpp-dependent
patterning of the D. schnurri wing, and restricts proliferation
of committed progenitors in the germline (36, 42–44).
However, the role of the three known vertebrate Shn
orthologues (Shn-1, Shn-2, and Shn-3/KRC) in the con-
text of BMP/TGF /activin signaling in development is
unknown. Smad family members have been shown to in-
teract with AP-1, raising the possibility that KRC may
form a tripartite complex (46, 47). Indeed, c-Jun has been
shown to associate with the oncoprotein Ski to suppress
Smad2 transcriptional activity (48). However, it may be
that the signaling pathways involved with Schnurri proteins
in the fly and in mammalian cells are distinct because we
have demonstrated that KRC is downstream of both the T
cell and TNF receptors. In addition, another member of
the D. schnurri family, Schnurri-2, is required for efficient
thymic positive selection (49). Mice lacking Shn-2 had se-
verely impaired positive selection of both CD4  and CD8 
T cells, although no mechanism for this phenotype was
presented. Thymic development appears normal in mice
lacking KRC (unpublished data), suggesting that distinct
Shn factors may serve distinct roles at different time points
in T cell development and function. It will be interesting
to determine whether Shn family members other than
KRC/Shn-3 serve as AP-1 coactivators. Thus, although D.
schnurri partners with members of the TGF /activin/dpp
pathway, it may be that mammalian Schnurri proteins func-
tion downstream of different signaling pathways. One such
signaling pathway is the T cell receptor. Upon TCR stim-
ulation, KRC expression dramatically increases, and KRC
physically associates with c-Jun to serve as a coactivator of
AP-1–dependent IL-2 gene transcription.
Coactivator proteins that potentiate transcriptional re-
sponses mediated by AP-1 have been reported previously
and include p300/CREB-binding protein (CBP), SRC-1,
ASC-2, and the   chain of the nascent polypeptide-associ-
ated complex ( -NAC), among others (35, 51–55). It is
likely that multiple coactivators contribute to the tissue
specificity of target gene activation by AP-1 proteins
through different mechanisms. For example,  -NAC is a
c-Jun homodimer-specific coactivator protein, whose tis-
sue distribution during embryogenesis is restricted to osteo-
blasts (54). In contrast, KRC coactivates both c-Jun ho-
modimers and the c-Jun/c-Fos heterodimer. Furthermore,
unlike  -NAC, which appears to stabilize the interaction
of the Jun homodimer to its cognate DNA binding site,
KRC does not affect AP-1 DNA binding activity in elec-
trophoretic mobility shift assays (unpublished data).
The Jun-activating binding protein 1 (JAB-1), isolated in
a yeast two-hybrid screen, selectively coactivates c-Jun and
Figure 5. KRC physically in-
teracts with c-Jun and acts as a
transcriptional coactivator. (A)
293T cells were transfected with
c-Jun and myc-KRCtr. 48 h
later, lysates were immunopre-
cipitated with anti-Myc anti-
body. Immunoprecipitates were
probed by Western blotting with
anti–c-Jun antibody. (B) 293T
cells were cotransfected with c-Jun
and full length His-KRC (left).
48 h later, lysates were immuno-
precipitated with anti-His anti-
body (DE8 Omniprobe), and
precipitates were probed by
Western blotting with anti–c-
Jun antibody. In vitro–translated
and S35-labeled c-Jun and His-
KRCtr were mixed and immu-
noprecipitated with anti-His
antibody (right). Recovered c-Jun
protein was visualized by autora-
diography. (C) Jurkat or EL4 T
cells were stimulated with PMA
plus ionomycin for 45 min. Ly-
sates were immunoprecipitated with anti–c-Jun antibody, and immunoprecipitates were probed with specific anti-KRC rabbit antisera. (D) 293T cells
were transfected with AP-1 luciferase along with c-Jun, c-Fos, and KRC (top). 24 h later, luciferase activity was determined as aforementioned. 293T
cells were transfected with GAL4 luciferase along with GAL4, GAL4–c-Jun 1-224, or GAL4–c-Fos 208-313 (bottom). 24 h later, luciferase activity was
determined as aforementioned.KRC Interacts with c-Jun to Regulate IL-2 in T Cells 22
JunD (58). JAB-1 stabilizes complexes of c-Jun and JunD at
their individual AP-1 binding sites, increasing the specificity
of target gene activation. In contrast with other AP-1 coacti-
vators, signals upstream of JAB1 under physiological condi-
tions have been identified. JAB1 appears to be required for
the AP-1 transcriptional activity that is triggered upon en-
gagement of the LFA1 accessory receptor (59). Interestingly,
JAB-1 does not appear to potentiate AP-1 activity after
TCR stimulation (unpublished data). In contrast, we have
shown that KRC coactivates AP-1 in the context of the IL-2
gene after TCR ligation. Thus, it appears that different ex-
tracellular stimuli can recruit different AP-1 coactivators.
Additional specificity of AP-1 coactivators may be pro-
vided by posttranslational modifications. CBP, for example,
interacts only with the NH2-terminal phosphorylated form
of c-Jun (35). However, JNK expression is very low in na-
ive Thp cells, and JNK1/2-deficient or c-Jun S63A/S73A
mutant CD4 T cells show no defect in IL-2 production af-
ter initial TCR stimulation, suggesting that AP-1 complexes
in naive Thp cells use a coactivator distinct from CBP (56,
57, 61). Although many proteins have been identified that
can serve as AP-1 coactivators in various overexpression sys-
tems, none have been studied under physiological condi-
tions with respect to interactions with AP-1 complexes in
the context of specific target genes. Furthermore, the tissue
distribution and cell type–specific signals regulating the ac-
tivity of these factors are unclear. Here, we present clear
gain- and loss-of-function data demonstrating that KRC is
both necessary and sufficient to potently regulate AP-1 ac-
tivity in the context of the IL-2 promoter in CD4  T cells
after CD3/CD28-mediated stimulation.
Other groups have reported a function for KRC as a
DNA-binding transcription factor (11). In our studies,
KRC appears to promote IL-2 gene expression via its in-
teractions with c-Jun, as a coactivator. Indeed, certain
DNA-binding transcription factors, such as c-Jun itself, can
also function as coactivators for specific target genes dem-
onstrating that the role assigned to a nuclear factor must be
carefully designated based on functional evidence in a pro-
moter-specific fashion (60).
KRC may be both upstream and downstream of AP-1
because signaling through the TCR, which induces KRC
expression, acts in part through inducing AP-1 itself. It is
tempting to postulate the existence of a self-reinforcing
feedback loop between KRC and AP-1 that serves to am-
plify membrane signaling. This type of positive regulatory
loop in the context of mechanisms regulating AP-1 func-
tion is not unprecedented; sustained, but not transient,
ERK activation downstream of platelet-derived growth
factor signaling in fibroblasts results in both c-Fos mRNA
induction and stabilization of c-Fos protein, greatly poten-
tiating AP-1 activity (50). Future work will be necessary to
define the precise mechanism via which KRC acts as an
AP-1 coactivator in the context of the IL-2 gene in T cells.
Additionally, the use of KRC-null mice will allow a more
global analysis of the role of KRC in regulating AP-1–
dependent transcription in all cell types.
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